GlassScriptPhysician profile
Joseph Chao
NPI 1285831057
$109,640.50
in general payments reported to CMS, 2019-2025
19 companies · $30.51 in 2025
The $30.51 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $26K · 2021: $30K · 2022: $25K · 2023: $1,800 · 2024: $28.23 · 2025: $30.51.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,800 · Food and Beverage: $58.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,800.00 |
| Food and Beverage | $58.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $43,929.45 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $22,050.00 | 2020-2023 | |
| Lilly USA, LLC | $11,917.60 | 2019-2021 | |
| F. Hoffmann-La Roche Ag | $8,415.00 | 2022 | |
| Daiichi Sankyo INC. | $7,988.26 | 2019-2022 | |
| Amgen INC. | $6,446.00 | 2020 | |
| Astrazeneca Uk Limited | $2,397.50 | 2021 | |
| Foundation Medicine, INC. | $1,828.51 | 2019 | |
| Taiho Oncology, INC. | $1,800.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $1,637.50 | 2021 | |
| Coherus Oncology, INC. | $900.00 | 2021 | |
| Dova Pharmaceuticals | $149.52 | 2019 | |
| Biocryst US Sales Co., LLC | $98.17 | 2022 | |
| Abbvie INC. | $58.74 | 2024-2025 | |
| Array Biopharma INC | $24.25 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Chao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.